Drug Trial Radar · NCT01884948
Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection
Last checked: Nov 20, 2026Latest source record: Jun 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
258
Planned (sponsor's estimate)
Start
Jul 2013
Primary completion
Mar 2016
Study completion Mar 2016
Sponsor
- Lead sponsor
- University of ZurichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 24, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To study the efficacy and safety of intravenous Omegaven™ (vs. Placebo) in reducing postoperative morbidity and mortality after major liver resection.
Conditions
- Major Liver Surgery
Interventions
Omegaven™Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Postoperative complicationsTime frame: 1 month after hospital discharge
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital Zurich, Visceral and Transplantation Surgery
Zurich, Canton of Zurich, Switzerland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.